TNFAIP3 and psoriasis: Recently, a preliminary study with 20 Spanish patients diagnosed with psoriasis and psoriatic arthritis assessed the relationship between these polymorphisms (TNFAIP3 rs610604 and TNFAIP3 rs6920220) and improvement in the quality of life of patients treated with anti-TNF drugs (European quality of life visual analog scale (EQ-VAS) score at 3 and 6 months), finding statistically significant results at three months of treatment (TNFAIP3 rs610604-AC/CC: OR = −10.60, CI95% = −20.71–−0.48, p = 0.041; TNFAIP3 rs6920220-AA: OR = −25.83, CI95% = −47.969–−3.698, p = 0.025) [85].